Post

New research · Pulmonology & Critical Care
Archivos de bronconeumologia · 2d
GuidelineArchivos de bronconeumologia · 2026

Spanish Clinical Practice Guidelines for the Diagnosis and Management of Alpha-1 Antitrypsin Deficiency: 2026 Update.

Myriam Calle Rubio, José Luis López-Campos, Francisco Casas Maldonado … Marc Miravitlles
Read paper
Pulmonology & Critical CareGuideline

AAT levels below 116mg/dL trigger a two-step diagnostic approach for deficiency.

Spanish Clinical Practice Guidelines for the Diagnosis and Management of Alpha-1 Antitrypsin Deficiency: 2026 Update.

Myriam Calle Rubio et al. · Archivos de bronconeumologia · 2026
Background

AATD remains substantially underdiagnosed and is often diagnosed late; consequently, many individuals with severe deficiency do not benefit from disease-specific counseling or tailored care modifications.

Methods

A systematic review was conducted using the GRADE and ADOLOPMENT frameworks, with an updated literature review that, together with expert opinion, served as the basis for formulating recommendations.

116mg/dL
Results
lower alpha-1 antitrypsin protein levels than this trigger a two-step diagnosis
More results

Alpha-1 antitrypsin deficiency (AATD) is a genetic condition characterized by reduced blood levels of alpha-1 antitrypsin (AAT), which confers an increased risk of developing several disorders throughout life, mainly pulmonary emphysema and liver involvement.

More results

Since 2015, when the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) published an updated document on the detection and treatment of patients with chronic obstructive pulmonary disease (COPD) associated with AATD, new diagnostic procedures and studies on augmentation therapy have been developed.

“
Conclusion

The panel recommends augmentation therapy for patients with documented severe AATD, with a genotype associated with severe deficiency and AAT levels <57.2mg/dL (<11μmol/L), and with emphysema documented on computed tomography and impaired pulmonary function test results, who are receiving optimal pharmacologic and nonpharmacologic treatment and are not active smokers.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
AUROC > 0.8
The models were highly accurate at predicting circulatory and respiratory instability
Review
80.6%
most reinforcement learning studies for sepsis treatment used the MIMIC database
Cohort Study
adjusted hazard ratio 1.917
Patients with leukoerythroblastosis had a 1.9-fold higher hazard of 90-day death.
Cohort Study
0.84
the model performed well in identifying patients at higher risk for ventilator-associated pneumonia
Cohort Study
OR: 2.172
sepsis-related clotting issues are associated with over twice the odds of hospital death
Cohort Study
OR 2.22
being COVID-19 positive meant a higher chance of dying in the hospital
Cohort Study
odds ratio = 0.273
morphine was associated with a lower risk of delirium compared to fentanyl